Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSPORT: Gosuranemab in Progressive Supranuclear Palsy
NCT03068468Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing Gosuranemab with Placebo (2 arms). Primary endpoints: Progressive Supranuclear Palsy Rating Scale at 52 weeks and Safety and Tolerability at 52 weeks. Started Jun 2017; status: terminated.
02
Drugs
gosuranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03068468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068468.